Rating Change
Baird reiterated its Outperform rating on Axsome Therapeutics, Inc. (NASDAQ:AXSM) on November 03, 2026.
reiterateNASDAQ:AXSM
Baird Reiterates Outperform Rating on Axsome Therapeutics, Inc. (AXSM)
Baird reiterated its Outperform rating on Axsome Therapeutics, Inc. (NASDAQ:AXSM) on November 03, 2026.
At publication ·
What changed
Axsome Therapeutics, Inc. (NASDAQ:AXSM) · reiterate
- Firm
- Baird
- Rating
- Outperform to Outperform
- Price at event
- $142.99
- Market capitalization
- $7.5B
At a glance
Key takeaways
- Baird maintained an Outperform rating on Axsome Therapeutics (AXSM) on November 3, 2026, with the stock trading at $142.99 and a market capitalization of $7.5 billion.
Market Context
Axsome Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $142.99 with a market capitalization of $7.5B. The stock has gained 0.8% over the past 52 weeks.
Analyst coverage from Baird provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Axsome Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Axsome Therapeutics, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 03, 2026 | Guggenheim | Buy | N/A |
| Nov 03, 2026 | Baird | Outperform | N/A |
| Oct 26, 2026 | Piper Sandler | Overweight | N/A |
| Oct 08, 2026 | RBC Capital | Outperform | N/A |
| Sep 29, 2026 | Deutsche Bank | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View AXSM Stock Page
Frequently Asked Questions
What does the Outperform rating mean for AXSM?
A rating of Outperform from Baird reflects the analyst's outlook on Axsome Therapeutics, Inc. (NASDAQ:AXSM). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the AXSM forecast page.
